How many institutions held AQST - Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value in Q3 2025?

151 institutional investors reported AQST - Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value for Q3 2025. Use the holders table for investor-level position and value details.

Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST)

Q: What does CUSIP 03843E104 represent in this 13F holders report?

CUSIP 03843E104 is the security identifier for AQST - Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value used to aggregate holder disclosures.

CUSIP: 03843E104

Q3 2025 13F Holders as of 30 Sep 2025

Type / Class: Equity / Common Stock, $0.001 par value
Shares outstanding: 120,192,308
Total 13F shares: 66,072,635
Share change: +18,472,494
Total reported value: $369,385,999
Put/Call ratio: 58%
Price per share: $5.59
Number of holders: 151
Value change: +$106,443,073
Number of buys: 99
Number of sells: 42

Quarterly Holders Quick Answers

What is CUSIP 03843E104?
CUSIP 03843E104 identifies AQST - Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q4 2025
Previous quarter: Q2 2025

Recent filing periods for CUSIP 03843E104:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of AQST - Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
BlackRock, Inc.	13D/G 13F	Company	5.3%	6,426,343	$35,923,900	$0	30 Sep 2025	13D/G 13F
RTW INVESTMENTS, LP	13D/G	—	5.2%	6,250,000	$34,937,500	$0	30 Sep 2025	13D/G
Bratton Capital Management, L.P.	13F	Company	8.2%	9,810,958	$32,474,271	—	30 Jun 2025	13F
Douglas K. Bratton	13D/G 3/4/5	BRATTON DOUGLAS K · 10%+ Owner	11%	10,077,434	$28,720,687	$0	31 Dec 2024	13D/G 3/4/5
VANGUARD GROUP INC	13F	Company	3.6%	4,328,505	$14,327,352	—	30 Jun 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	2.5%	2,979,840	$9,863,270	—	30 Jun 2025	13F
Venrock Healthcare Capital Partners III, L.P.	13D/G	—	2.9%	2,629,786	$7,494,890	$0	31 Dec 2024	13D/G
PERCEPTIVE ADVISORS LLC	13F	Company	1.8%	2,190,420	$7,250,290	—	30 Jun 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.6%	1,977,001	$6,544,870	—	30 Jun 2025	13F
Pale Fire Capital SE	13F	Company	1.4%	1,676,451	$5,549,053	—	30 Jun 2025	13F
STATE STREET CORP	13F	Company	1.3%	1,507,298	$4,989,156	—	30 Jun 2025	13F
Alexander Mark Schobel	3/4/5	Chief Innovation/Tech Officer	— mixed-class rows	1,075,726 mixed-class rows	$4,804,243	—	15 Mar 2024	3/4/5
MORGAN STANLEY	13F	Company	1.2%	1,414,061	$4,680,543	—	30 Jun 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	1.1%	1,283,140	$4,247,193	—	30 Jun 2025	13F
Janney Montgomery Scott LLC	13F	Company	0.88%	1,053,060	$3,486,000	—	30 Jun 2025	13F
Sio Capital Management, LLC	13F	Company	0.79%	947,489	$3,136,189	—	30 Jun 2025	13F
Blue Owl Capital Holdings LP	13F	Company	0.77%	920,000	$3,045,200	—	30 Jun 2025	13F
Everstar Asset Management, LLC	13F	Company	0.55%	658,607	$2,179,989	—	30 Jun 2025	13F
NORTHERN TRUST CORP	13F	Company	0.54%	643,919	$2,131,373	—	30 Jun 2025	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.46%	551,700	$1,826,127	—	30 Jun 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.44%	524,685	$1,736,708	—	30 Jun 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.39%	466,761	$1,544,979	—	30 Jun 2025	13F
Bracebridge Capital, LLC	13F	Company	0.38%	459,216	$1,520,005	—	30 Jun 2025	13F
JPMORGAN CHASE & CO	13F	Company	0.36%	435,972	$1,443,067	—	30 Jun 2025	13F
Woodline Partners LP	13F	Company	0.34%	407,661	$1,349,358	—	30 Jun 2025	13F
STIFEL FINANCIAL CORP	13F	Company	0.31%	374,228	$1,238,694	—	30 Jun 2025	13F
UBS Group AG	13F	Company	0.3%	361,264	$1,195,784	—	30 Jun 2025	13F
HARVEY CAPITAL MANAGEMENT INC	13F	Company	0.28%	333,755	$1,134,767	—	30 Jun 2025	13F
ROYAL BANK OF CANADA	13F	Company	0.28%	341,419	$1,130,000	—	30 Jun 2025	13F
Financial Engines Advisors L.L.C.	13F	Company	0.23%	272,686	$903,000	—	30 Jun 2025	13F
Stephen Wargacki	3/4/5	Chief Science Officer	— mixed-class rows	464,802 mixed-class rows	$872,622	—	07 Mar 2025	3/4/5
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	0.2%	245,299	$811,939	—	30 Jun 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.2%	244,396	$808,951	—	30 Jun 2025	13F
Latash Investments, LLC	13F	Company	0.2%	243,134	$804,774	—	30 Jun 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.2%	239,914	$794,115	—	30 Jun 2025	13F
Walleye Capital LLC	13F	Company	0.2%	237,904	$787,462	—	30 Jun 2025	13F
Nuveen, LLC	13F	Company	0.17%	201,417	$666,690	—	30 Jun 2025	13F
GSA CAPITAL PARTNERS LLP	13F	Company	0.16%	186,692	$618,000	—	30 Jun 2025	13F
Bank of New York Mellon Corp	13F	Company	0.15%	184,916	$612,071	—	30 Jun 2025	13F
OSAIC HOLDINGS, INC.	13F	Company	0.15%	175,541	$581,036	—	30 Jun 2025	13F
Diametric Capital, LP	13F	Company	0.14%	165,373	$547,384	—	30 Jun 2025	13F
BARCLAYS PLC	13F	Company	0.13%	153,828	$509,171	—	30 Jun 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.13%	152,156	$503,636	—	30 Jun 2025	13F
EntryPoint Capital, LLC	13F	Company	0.12%	149,156	$493,706	—	30 Jun 2025	13F
DAFNA Capital Management LLC	13F	Company	0.12%	142,000	$470,020	—	30 Jun 2025	13F
RHUMBLINE ADVISERS	13F	Company	0.12%	140,872	$466,277	—	30 Jun 2025	13F
John Cochran	3/4/5	Director	— mixed-class rows	141,486 mixed-class rows	$441,678	—	11 Jun 2025	3/4/5
Russell Investments Group, Ltd.	13F	Company	0.11%	127,704	$422,701	—	30 Jun 2025	13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.1%	117,700	$389,587	—	30 Jun 2025	13F
Gregory B. Brown	3/4/5	Director	— mixed-class rows	117,085 mixed-class rows	$368,475	—	11 Jun 2025	3/4/5

Institutional Holders of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) as of Q3 2025

As of 30 Sep 2025, Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) was held by 151 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 66,072,635 shares. The largest 10 holders included Bratton Capital Management, L.P., BlackRock, Inc., RTW INVESTMENTS, LP, VANGUARD GROUP INC, PERCEPTIVE ADVISORS LLC, EcoR1 Capital, LLC, SAMSARA BIOCAPITAL, LLC, GEODE CAPITAL MANAGEMENT, LLC, STATE STREET CORP, and Sio Capital Management, LLC. This page lists 151 institutional shareholders reporting positions in this security for the Q3 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q3 2025 vs Q2 2025 Across Filers

Q2 2025 holders

115

Q3 2025 holders

151

Holder diff

Investor	Q2 2025 Shares	Q3 2025 Shares	Share Diff	Share Chg %	Q2 2025 Value $	Q3 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.